Research on tumor cells in lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on studying the molecular and cell biology of tumor cells in patients with Hodgkin's disease and non-Hodgkin's lymphoma. By analyzing these cells, the study aims to gain insights into how lymphoma develops and spreads. The findings may contribute to the creation of new materials for future treatments or monitoring responses to existing therapies. The study involves collecting tissue samples from patients undergoing routine procedures, such as lymph node excision.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.
* Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).
* A routine procedure for tissue collection is planned.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Patients without NHL or Hodgkin's disease

Where it's running

• Stanford University School of Medicine
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: Ronald Levy, MD — Stanford University
• Study coordinator: Alyssa M Kanegai
• Email: akanegai@stanford.edu
• Phone: 650-736-1596

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JMBI-001 in MYC-Positive Advanced Cancers

  This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.

  Recruiting Phase 1/2 Chengdu Anticancer Bioscience, Ltd. · Beijing, Beijing Municipality · NCT07864701

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

  We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.

  Recruiting at 22 sites Phase 1/2 GlaxoSmithKline · Iowa City, Iowa and 21 other locations · NCT07607925

• AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients

  This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.

  Recruiting Grand Hôpital de Charleroi · Charleroi, Hainaut · NCT07546188

• MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma

  This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.

  Recruiting at 54 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 53 other locations · NCT07519772

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.